Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Bloomage BioTechnology Corporation Limited
  6. Summary
    688363   CNE100003NL9

BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED

(688363)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
126.31 127.8 123.97 123.04 119.78 Last
2363889 1481757 1697010 1345306 1602271 Volume
-3.06% +1.18% -3.00% -0.75% -2.65% Change
Estimated financial data (e)
Sales 2021 4 392 M 690 M 690 M
Net income 2021 809 M 127 M 127 M
Net cash position 2021 65,1 M 10,2 M 10,2 M
P/E ratio 2021 70,7x
Yield 2021 0,43%
Sales 2022 6 256 M 983 M 983 M
Net income 2022 1 149 M 181 M 181 M
Net cash position 2022 164 M 25,7 M 25,7 M
P/E ratio 2022 50,2x
Yield 2022 0,59%
Capitalization 57 494 M 9 033 M 9 034 M
EV / Sales 2021 13,1x
EV / Sales 2022 9,16x
Nbr of Employees 2 876
Free-Float -
More Financials
Company
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED is a China-based company mainly engaged in the research, development, production and sales of various raw materials of sodium hyaluronate and relevant bioactive ingredients, as well as end products such as medicines, medical devices and functional skin care products. The Company relies on microbial fermentation and cross-linking technology platforms to provide raw materials... 
Sector
Pharmaceuticals
Calendar
03/23Earnings Release
More about the company
Ratings of Bloomage BioTechnology Corporation Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
2021BLOOMAGE BIOTECHNOLOGY CORPORATION L : 688363) added to Shanghai Stock Exchange 180 Value ..
CI
2021BLOOMAGE BIOTECHNOLOGY CORPORATION L : 688363) added to SSE 180 Index
CI
2021Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Nine Months..
CI
2021Chinese State Media Calls For False Advertising Crackdown in Medical Beauty Ads
MT
2021Bloomage Biotechnology Corporation Limited Reports Earnings Results for the Half Year E..
CI
2021China Signals Regulatory Clampdown on Medical Beauty Sector
MT
2021China stocks slip as healthcare firms retreat; Hong Kong up
RE
2021BLOOMAGE BIOTECHNOLOGY CORPORATION L : 688363) added to Shanghai Stock Exchange Health Car..
CI
2021Bloomage Biotechnology Corporation Limited Reports Earnings Results for the First Quart..
CI
2021Bloomage BioTechnology Corporation Limited acquired Dongyin Foster.
CI
2021Bloomage Biotechnology Corporation Limited Reports Earnings Results for the Full Year E..
CI
2020Bloomage BioTechnology Corporation Limited completed the acquisition of Dongying Fusite..
CI
2020Bloomage Biotechnology Corporation Limited Announces Earnings Results for the First Hal..
CI
2020Bloomage Biotechnology Corporation Limited Announces Cash Dividend on A Share for 2019,..
CI
2020Bloomage BioTechnology Corporation Limited signed an equity transfer agreement to acqui..
CI
More news
News in other languages on BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
2020Bloomage Biotechnology Corporation Limited annonce un dividende en espèces sur l'action..
More news
Chart BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
Duration : Period :
Bloomage BioTechnology Corporation Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 119,78 CNY
Average target price 203,61 CNY
Spread / Average Target 70,0%
EPS Revisions
Managers and Directors
Yan Zhao Chairman & General Manager
Jia Jun Guo CFO, COO, Director & Deputy General Manager
Jing Yu Chairman-Supervisory Board
Xue Ping Guo Director, Chief Scientist & Deputy General Manager
Ying Qian Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED-22.87%9 343
CSL LIMITED-11.13%88 612
WUXI BIOLOGICS (CAYMAN) INC.-16.59%43 139
SAMSUNG BIOLOGICS CO.,LTD.-21.15%41 851
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.47%32 258